Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.48 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.43 |
| ▸ | WDR77 | Q9BQA1 | 3/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 3/20 | 0.42 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.41 |
| ▸ | GHSR | Q92847 | 2/20 | 0.41 |
| ▸ | ACE | P12821 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18066403 | 1.00 | MEN1 (0.50) | MEN1KMT2AMTNR1BPRMT5WDR77 | |
| SCHEMBL30558539 | 1.00 | MEN1 (0.50) | MEN1KMT2AMTNR1BPRMT5WDR77 | |
| SCHEMBL30429107 | 0.90 | MTNR1B (0.46) | MEN1KMT2AMTNR1BPRMT5WDR77 | |
| SCHEMBL4839514 | 0.90 | MTNR1B (0.46) | MEN1KMT2AMTNR1BPRMT5WDR77 | |
| SCHEMBL12162581 | 0.90 | MTNR1B (0.48) | MEN1KMT2AMTNR1BPRMT5WDR77 | |
| SCHEMBL30558637 | 0.89 | MTNR1B (0.47) | MEN1KMT2AMTNR1BPRMT5WDR77 | |
| SCHEMBL18085750 | 0.89 | MTNR1B (0.47) | MEN1KMT2AMTNR1BPRMT5WDR77 | |
| SCHEMBL4662999 | 0.89 | MTNR1B (0.47) | MEN1KMT2AMTNR1BPRMT5WDR77 | |
| SCHEMBL11929926 | 0.89 | MTNR1B (0.47) | MEN1KMT2AMTNR1BPRMT5WDR77 | |
| SCHEMBL30428513 | 0.88 | MTNR1B (0.45) | MEN1KMT2AMTNR1BPRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111909083-B | Inhibitors of histone demethylase | 赛尔基因昆蒂赛尔研究公司 | 2023-08-15 | — | — | CN | disclosed |
| EP-3160952-B1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2020-12-02 | — | — | EP | disclosed |
| EP-3741749-A1 | HISTONE DEMETHYLASE INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2020-11-25 | — | — | EP | disclosed |
| EP-3738960-A1 | HISTONE DEMETHYLASE INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2020-11-18 | — | — | EP | disclosed |
| CN-111909083-A | Histone demethylase inhibitors | 赛尔基因昆蒂赛尔研究公司 | 2020-11-10 | — | — | CN | disclosed |
| CN-106660982-B | Histone demethylase inhibitors | 赛尔基因昆蒂赛尔研究公司 | 2020-09-08 | — | — | CN | disclosed |
| US-10385047-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-10106534-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-10-23 | — | — | US | disclosed |
| US-20180251458-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-09-06 | — | — | US | disclosed |
| US-9994561-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| WO-2015200709-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2015-12-30 | — | — | WO | disclosed |
| EP-2683710-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | Boehringer Ingelheim International GmbH (DE) | 2014-01-15 | — | — | EP | disclosed |
| US-8569339-B2 | Soluble guanylate cyclase activators | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-29 | — | — | US | disclosed |
| US-20130065918-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-03-14 | — | — | US | disclosed |
| WO-2012122340-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-13 | — | — | WO | disclosed |
| US-20080176838-A1 | Dpp-IV Inhibitors | SANTHERA PHARMACEUTICALS (DEUTSCHLAND) AG (DE) | 2008-07-24 | — | — | US | disclosed |
| CN-101005835-A | 1-[(3r)-amino-4-(2-fluoro-phenyl)-butyl]-pyrrolidine-(2r)-carboxylic acid-benzyl amine derivatives and related compounds as dipeptidyl-peptidase iv (dpp-iv) inhibitors for the treatment of type 2 diab | SANTHERA PHARMACEUTICALS CH (CH) | 2007-07-25 | — | — | CN | disclosed |
| EP-1791536-A1 | 1-[(3R)-AMINO-4-(2-FLUORO-PHENYL)-BUTYL]-PYRROLIDINE-(2R)-CARBOXYLIC ACID-BENZYL AMINE DERIVATIVES AND RELATED COMPOUNDS AS DIPEPTIDYL-PEPTIDASE IV (DPP-IV) INHIBITORS FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2007-06-06 | — | — | EP | disclosed |
| WO-2005120494-A1 | 1-`(3R)-AMINO-4-(2-FLUORO-PHENYL)-BUTYL !-PYRROLIDINE-(2R)-CARBOXILIC ACID-BENZYL AMINE DERIVATIVES AND RELATED COMPOUNDS AS DIPEPTIDYL-PEPTIDASE IV (DPP-IV) INHIBITORS FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2005-12-22 | — | — | WO | disclosed |
| EP-1604662-A1 | 1-[(3R)-Amino-4-(2-fluoro-phenyl)-butyl]-pyrrolidine-(2R)-carboxylic acid benzyl amine derivatives and related compounds as dipeptidyl peptidase IV (DPP-IV) inhibitors for the treatment of type 2 diabetes mellitus | Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft (DE) | 2005-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180251458-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM6A, KDM1A | MEN1 3059/4885KMT2A 47/4885MTNR1B 1576/4885 |
| US-20130065918-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | GUCY1A1, GUCY1A2, GUCY1B1 | MEN1 843/4885KMT2A 4392/4885MTNR1B 1434/4885 |
| US-10106534-B2 | Histone demethylase inhibitors | KDM1B, KDM6A, KDM1A | MEN1 3059/4885KMT2A 47/4885MTNR1B 1576/4885 |
| US-10385047-B2 | Histone demethylase inhibitors | KDM1B, KDM6A, KDM1A | MEN1 3059/4885KMT2A 47/4885MTNR1B 1576/4885 |
| US-20080176838-A1 | Dpp-IV Inhibitors | DPP4, DPP9, DPP7 | MEN1 4498/4885KMT2A 1391/4885MTNR1B 308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.